Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28453)	3/2/1999 6:11:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 32384

Could SERMs (like Evista)that promote "good cholesterol" and triglycerides profiles balance out Targretin's "bad" triglycerides changes and allow the combination to be used in breast cancer prevention? for cases of very high risk (women who get surgical removal of the breasts without any disease just for prevention and the like). Later when 2nd and 3rd generation drugs are developed then they will be first option instead of Targretin. Tamoxifen (to my knowledge)has not shown pro-cardiac effects. Evista is already proven to improved the "good" cholesterol, and a large 10,000 patients (and 10 years?)study is ongoing to determine if that translates into actual heart attacks/stroke prevention. Other SERMs (from Lgnd)could prove to be useful the same way as Evista. Other probable markets for SERMs is for men osteoporosis in old age, and men cardiac health prevention (like Evista effects in women).